Bromodeoxyuridine (BrdU): Analysis of cell kinetics;La bromodeoxyuridine (BrdU): Analyse des proliferations cellulaires

Annales de Pathologie

Volumn 17, Issue 3, 1997, Pages 171-178

  Bosq, J ^a   Bourhis, J ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

BUdr; Cell kinetics; Cellular cycle

Indexed keywords

BROXURIDINE; MONOCLONAL ANTIBODY; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE; CELL PROLIFERATION; HUMAN; STOMACH CANCER; ANIMAL; BIOPSY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; NEOPLASM; REFERENCE VALUE; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOPSY; BROMODEOXYURIDINE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 0030843128     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. TUBIANA M, PEJOVIC MH, KOLSCIELNY S, CHAVAUDRA N, MALAISE EP. Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer 1989 ; 44 : 17-22.
2. BREUR K. Growth rate and radiosensitivity of human tumours. Den Haag : Mouton & Co 1965.
3. TUBIANA M. Gray medal lecture : cell kinetis and radiation oncology. Int J Radiat Oncol Biol Phys 1982 ; 8 : 1471-89.
4. TRERÉ D. Critical analysis of the methods commonly employed in the assessment of cell proliferation : advantages of the NOR silver-staining technique in routine cyto-histopathology. Anal Cell Path 1993 ; 5 : 191-201.
5. GRATZNER HG. Monoclonal antibody to 5-bromo and 5-iododeoxyuridine : a new reagent for detection of DNA replication. Science 1982 ; 218 : 474-5.
6. STEEL GG. Growth kinetics of tumours. Oxford University Press. 1977.
7. BEGG AC, Mc NALLY NJ, SHRIEVE DC, KARCHER H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985 ; 6 : 620-22.
8. SASAKI K, OGINO T, TALAHASHI M. Immunological determination of labeling index on human tumor tissue section using monoclonal anti-BrdU antibody. Stain Technol 1986 ; 61 : 155-61.
9. SASAKI K, OGINO T, TALAHASHI M. In vitro BrdU labeling of solid tumors and immunological determination of labeling index. J Histotechnol 1987 ; 10 : 47-49.
10. BENNETT MH. In vivo labelling of human tumours with bromo-deoxyuridine : a histopathologist's view. Br J Radiol 1992 ; 24 (suppl) : 168-73.
11. RICCARDI A, DANOVA M, DIOMIGI P, DOMINIA P. Cell kinetics in leukemia and solid tumour studied with bromodeoxyuridine and flow cytometry. Br J Cancer 1989; 59 : 898-903.
12. WILSON GD, Mc NALLY NJ, DUNPHY E, KARCHER H, PFRAGNER R. The labelling index of human and mouse tumours assessed by bromodeoxyuridine staining in vivo and in vitro and flow cytometry. Cytometry 1985 ; 5 : 641-7.
13. BOURHIS J, WILSON GD, JANOT F, CHAVAUDRA N, LERIDANT AM, WIBAULT et al. Mesure de la cinétique de prolifération in vivo des cancers de l'oropharynx par incorporation de bromode-soxyuridine et cytométrie de flux. Bull Cancer 1991 ; 78 : 1045-51.
14. RONCUCCI L, PEDRONI M, SCALMATI A, BORMIOLI ML, SASSATELLI R, FANTI R et al. Cell kinetics evaluation of colorectal tumors after in vivo administration of bromodeoxyuridine. Int J Cancer 1992 ; 52 : 856-61.
15. MEYER JS, NAUERT J, KOEHM S, HUGHES J. Cell kinetics of human tumors by in vitro bromodeoxyuridine labeling. J Histochem Cytochem 1989 ; 37(9) : 1449-54.
16. WILSON GD, Mc NALLY NJ, DISCHE S, SAUNDERS MI, Des ROCHERS C, LEWIS AA et al. Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer 1988 ; 58 : 423-31.
17. BEGG AC, HOFLAND L, MOONEN H, BARTELINK H, SCHRAUB S, BONTEMPS P et al. The predictive value of cell kinetic measurement in a European trial of accelerated fractionation in advanced head and neck tumors : an interim report. Int J Radiat Oncol Biol Phys 1990 ; 19 : 1449-53.
18. RISIO M, COVERLIZZA S, FERRARI A, CANDELARESI GL, ROSSINI FP. Immunohistochemical study of epithelial cell proliferation in hyperplastic polyps, adenomas and adenocarcinomas of the large bowel. Gastroenterology 1988 ; 94 : 899-906.
19. RICCARDI A, DANOVA M, WILSON G, UCCI G, DORMER P, MAZZINI G et al. Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry. Cancer Res 1988 ; 48 : 6238-45.
20. Goz B. The effects of incorporation of 5-halogenated deoxyuridines into the DNA of eukaryotic cells. Pharmacol Rev 1978 ; 29 : 249-72.
21. HAUSTERMANS K. In vivo growth kinetic measurements in human eosophageal cancer. Thèse de Doctorat en médecine - Faculteit der Geneeskunde - Katholieke Universiteit Leuven. 1995.
22. HAUSTERMANS K, HOFLAND I, POTTIE G, RAMAEKERS M, BEGG AC. Can measurements of potential doubling time (Tpot) be compared between laboratories ? A quality control study. Cytometry 1995 ; 19,2 : 154-63.
23. PARKINS CS, BEGG AC. BUSH C, PRICE P, IMRIE PR, OMEROD MG et al. In vivo bromodeoxyuridine labelling in human tumour xeno-grafts. Int J Radiat Biol 1989 ; 56,5 : 787-91.
24. BEGG AC, MOONEN H, DESSING M, BARTELINK H. Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine : intratumoral sampling variations. Radiother Oncol 1988 ; 11 : 337-47.
25. BEGG AC, MOONEN L, HOFLAND I, DESSING M, BARTELINK H. Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine : intratumour sampling variation. Radiother Oncol 1988 ; 11 : 337-47.
26. REW DA, CAMPBELL ID, TAYLOR I, WILSON GD. Proliferation indices of invasive breast carcinomas after in vivo 5-bromo-2'deoxyuridine labelling : a flow cytometric study of 75 tumours. Br J Surg 1992 ; 79 : 335-9.
27. HAUSTERMANS K, VANUYSTEL L, GEBOES K, LERUT T, VAN THILLO J, LEYSEN J et al. « In vivo cell kinetic measurements in human oesophageal cancer : what can be learned from multiple biopsies ? » Eur J Cancer 1994 , 30A, 12 : 1787-91.
28. BENNETT MH, WILSON GD, DISCHE S, SAUNDERS MI, MARTINDALE CA, ROBINSON BM et al. Tumour proliferation assessed by combined histological and flow cytometric analysis : implications for therapy in squamous cell carcinoma in the head and neck. Br J Cancer 1992 ; 65 : 870-8.
29. HIRANO T, ZITSCH RP. GLUCKMAN JL. The use of bromodeoxyuridine cytokinetic studies as a prognostic indicator of cancer of the head and neck. Laryngoscope 1991 ; 101 : 130-3.
30. LIMAS C, BIGLER A, BAIR R, BERNHART P, REDDY P. Proliferative activity of urothelial neoplasms : comparison of BrdU incorporation, Ki67 expression, and nucleolar organiser regions. J Clin Pathol 1993 ; 46 : 159-65.
31. BEGG AC, HOFLAND I, MOONEN L, BARTELINK H, SCHRAUB S, BONTEMPS P et al. The predictive value of cell kinetic measurements in a european trial of accelerated fractionation in advanced head and neck tumors : an interim report. Int J Radiat Oncol Biol Phys 1990 ; 19 : 1449-53.
32. HEMMER J. In vitro bomodeoxyuridine labelling of squamous cell carcinomas of the oral cavity. Eur J Cancer 1990 ; 26 : 113-15.
33. CHAUVEL P, COURDI A, GIONNI J et al. The labelling index : a prognostic factor in head and neck carcinoma. Radiother Oncol 1989 : 14 : 231-37.
34. BOURHIS J, WILSON G, WIBAULT P, BOSQ J, CHAVAUDRA N, JANOT F et al. In vivo measurement of the potential doubling time by flowcytometry in oropharyngeal cancer treated by conventional radiotherapy. Int J Radiat Onco Biol Phys 1993 ; 26 : 793-9.
35. BEGG AC, HOFLAND I, VAN GLABBEKE M, BARTELINK H, HORIOT JC. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients : results from the EORTC cooperative trial 22851. Semin Radiat Oncol 1992 ; 1 : 22-5.
36. BOURHIS J, BOSQ J, WILSON GD, BRESSAC B, WIBAULT P, TALBOT M et al. Correlation between P53 gene expression and tumor cell proliferation in oropharyngeal cancer. Int J Cancer 1994 ; 57(4) : 458-62.
37. BOURHIS J, WILSON G, JANOT F, WIBAULT P, BOSQ J, ARMAND JP et al. Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. Laryngoscope 1994 ; 104 468-72.
38. MORIKI T, TAKAHASHI T, TANIOKA F, YAMANE T, HARA H. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Path Res Pract 1995 ; 191 . 1122-32.
39. LLOVERAS B, EDGERTON S, THOR AD. Evaluation of in vitro Bromodeoxyuridine labeling of breast carcinomas with the use of a commercial kit. Am J Clin Pathol 1991 ; 95 : 41-7.
40. OHYAMA S, YONEMURA Y, MIYAZAKI I. Prognostic value of S-phase fraction and DNA ploidy studied with in vivo administration of bromodeoxyuridine on human gastric cancers. Cancer 1990; 65 : 116-21.
41. OHYAMA S, YUNUERA Y, MIYAZAKI I. Proliferate activity and malignancies in human gastric cancers. Significance of the proliferation rate and its clinician application. Cancer 1992 ; 69(2) : 314-21.
42. REW DA, WILSON GD, TAYLOR I, WEAVER PC. Proliferation characteristics of human colorectal carcinomas measured in vivo. Br J Surg 1991 ; 78 : 60-66.
43. SCOTT NA, WIEAND HS, MOERTEL CG, CHA SS, BEART RW, LIEBER MM. An investigation of differentiated methods of cell cycle analysis by flow cytometry in rectal cancer. Br J Cancer 1992 ; 65 : 8-10.
44. WITZIG TE, LOPRINZI CL, GONCHOROFF NJ. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 1991 ; 68 : 879-88.
45. HARLOW SP, ERIKSEN BL, POGGENSEE L et al. Prognostic implications of proliferative activity and DNA aneuploidy in Astler-Coller Dukes stage C colonic adenocarcinoma. Cancer Res 1991 ; 51 : 2403-09.
46. MEYER JS, PRIOLEAU PG. S-phase fractions of colorectal carcinomas related to pathologic and clinical features. Cancer 1981 , 48 : 1221-28.
47. BLEIBERG H, BUYSE M. GALAND P. Cell kinetic indicators of pre-malignant stages of colorectal cancer. Cancer 1985 ; 56 ; 124-29.
48. REW DA, WILSON GD, TAYLOR I, WEAVER PC. Proliferation characteristics of human colorectal carcinomas measured in vivo. Brit J Surg 1991 ; 78 : 60-6.
49. MELLON K, NEAL DE, ROBINSON MC, MARSH C, WEIGHT C. Cell cycling in bladder carcinoma, determined by monoclonal antibody Ki67. Br J Urol 1990 ; 66 : 281-5.
50. SHIBUYA M, SATOYUKI I, DAVIS RL, WILSON CB, HOSHINO T. A new method for analysing the cell kinetics of human brain tumors by double labeling with bromodeoxyuridine in situ and with iododeoxyuridine in vitro. Cancer 1993 ; 71 : 3109-13.
51. HOSHINO T, AHN D, PRADOS MD, LAMBORN K, WILSON CB. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labelling. Int J Cancer 1993 ; 53 : 550-55.
52. HOSHINO T, ITO S, ASAI A, SHIBUYA M, PRADOS MD, DODSON BA et al. Cell kinetic analysis of human brain tumors by in situ double labelling with BUdR and IUdR. Int J Cancer 1992 ; 50 : 1-5.
53. LANGFORD LA, COOKSLEY CS, DE MONTE F. Comparison of MIB-1 (Ki67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Hum Pathol 1996 ; 27 : 350-54.
54. SCHRAPE S, JONES DB, WRIGHT DH. A comparison of three methods for the determination of the growth fraction in non-Hodgkin's lymphoma. Br J Cancer 1987; 55 : 283-86.
55. BRONS PPT, HAANEN C, BOEZEMAN JBM, MUUS P, HOLDRINET SG et al. Proliferation patterns in acute myeloid leukemia : leukemic clonogenic growth and in vivo cell cycle kinetics. Ann Hematol 1993 ; 66 : 225-33.
56. GIORDANO M, DANOVA M, MAZZINI G, GOBBI P, RICCARDI A. Cell kinetics with in vivo Bromodeoxyuridine assay, proliferating cell nuclear antigen expression, and flow cytometric analysis. Cancer 1993 ; 71 : 2739-45.
57. ONDA K, DAVIS RL, SHIBUYA M, WILSON CB, HOSHINO T. Correlation between the Bromodeoxyuridine labeling index and the MIB-1 and Ki67 proliferating cell indices in cerebral gliomas. Cancer 1994 ; 74 : 1921-25.
58. DAVIS RL, ONDA K, SHUBUYA M, LAMBORN K, HOSHINO T. Proliferation markers in gliomas : a comparison of BrdU. Ki67, and MIB-1. J Neuro-Oncol 1995 ; 24 : 9-12.
59. SASAKI K, MATSUMURA K, TSUJI T, SHINOZAKI F, TAKAHASHI M. Relationship between labeling indices of Ki67 and BrdUrd in human malignant tumors. Cancer 1988 ; 62 : 989-93.
60. DAVIS RL, ONDA K, SHUBUYA M, LAMBORN K, HOSHINO T. Proliferation markers in gliomas : a comparison of BRDU, Ki67, and MIB-1. J Neuro Oncol 1995 ; 24 : 9-12.
61. GUINEBRETIÈRE M, SABOURIN JC. Ki-67, marqueur de prolifération. Ann. pathol 1997 ; 17 : 25-30.
62. MOURAD WA, CONNELLY JH, SEMBERA DL, ATKINSON EN, BRUNER JM. The correlation of two argyrophilic nucleolar organizer region counting methods with bromodeoxyuridine index. Hum Pathol 1993 ; 24 : 206-10.
63. GHNASSIA JP. L'antigène nucléaire de prolifération cellulaire (PCNA). Ann. Pathol 1996 ; 16 : 241-6.
64. CORVO R, GIARETTI W, SANGUINETI G, GEIDO E, ORECCHIA R, GUENZI M et al. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol 1995 ; 13 : 1843-50.
65. AWWAD HK, KHAFAGY Y, BARSOUM M, EZZAT M, EL-ATTAR I, FARAG H. Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer : influence of tumor proliferation. Radiother Oncol 1992 ; 25 : 261-66.
66. VALENTE G, ORECCHIA R, GANDOLFO S, ARNAUDO M, RAGONA R, KERIM S et al. Can Ki67 immunostaining predict response to radiotherapy in oral squamous cell carcinoma. J Clin Pathol 1994 ; 47 : 109-12.
67. SILVESTRINI R. Cell kinetics : prognostic and therapeutic implications in human tumours. Cell Prolif 1994 ; 27 : 579-96.
68. BEGG AC, HOFLAND I, KUMMERMEHR J. Tumor cell repopulation during fractionated radiotherapy. Correlation between flow cytometric and radiobiological data in three murine tumors. Eur J Cancer 1991 ; 27 : 537-43.
69. ALLAM A, PEREZ L, HUANG P. The effect of the overall treatment time of fractionated irradiation on the tumor control probability of a human soft tissue sarcoma xenograft in nude mice. Int J Radiat Oncol Biol Phys 1995 ; 32 : 105-11.
70. SPEKE AK, HILL RP. Repopulation kinetics during fractionated irradiation and the relationship to the potential doubling time. Int J Radiat Oncol Biol Phys 1995 ; 31 : 847-56.
71. DURAND RE. Cell kinetis and repopulation during multifraction irradiation of spheroids : implications for clinical radiotherapy. Semin Radiot Oncol 1993 ; 3 : 105-14.